Trial Profile
ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Etoposide (Primary) ; Thalidomide (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- Acronyms Angiocomb
- 18 Sep 2022 Status changed from recruiting to completed.
- 27 Dec 2012 Additional lead trial centers identified as reported by ClinicalTrials.gov.
- 27 Dec 2012 Planned number of patients changed from 10 to 50 as reported by ClinicalTrials.gov.